论文部分内容阅读
本实验对７０例卵巢浆液癌、１０例交界性癌、２０例卵巢浆液瘤中ＥＧＦＲ（表皮生长因子受体）、ｎｅｕ癌基因、ＰＣＮＡ（增殖细胞核抗原）表达进行研究，观察其在卵巢癌、交界性肿瘤、良性瘤的表达率，并采用半定量的ＡＢＣ免疫组化方法研究不同强度表达与病理分化、临床分期、预后的关系，得到初步结果。ＥＧＦＲ在浆液癌表达５８．５％，交界瘤５０％，浆液瘤５％，其表达率与预后呈负相关，与病理分化、临床分期无明显相关性。ｎｅｕ在卵巢浆液癌中表达４５．７％，交界瘤２０％，浆液瘤０，其阳性表达率及表达强度与预后和病理分化有关。ＰＣＮＡ在浆液癌中表达４７％，交界瘤中３０％，良性瘤１０％，其表达强度与预后和病理分化有关。本实验表明ＥＧＦＲ、ｎｅｕ、ＰＣＮＡ与卵巢浆液癌预后有相关性，ｎｅｕ、ＰＣＮＡ与病理分化也有一定相关性。可能成为判断病理分化、临床预后的指标。
In this study, the expression of EGFR (epidermal growth factor receptor), neu oncogene and PCNA (proliferating cell nuclear antigen) in 70 cases of ovarian serous carcinoma, 10 cases of borderline carcinoma and 20 cases of ovarian serous carcinoma were studied. Borderline tumors and benign tumors. The semi-quantitative ABC immunohistochemical method was used to study the relationship between different intensity expressions and pathological differentiation, clinical stage and prognosis, and the preliminary results were obtained. The expression of EGFR was 58.5% in serous carcinoma, 50% in borderline tumor and 5% in serous tumor. The expression rate of EGFR was negatively correlated with prognosis, but not with pathological differentiation and clinical stage. neu was expressed in 45.7% of ovarian serous carcinomas, 20% of borderline tumors and 0 in serous tumors. The positive expression rate of neu was correlated with the prognosis and pathological differentiation. The expression of PCNA was 47% in serous carcinoma, 30% in border tumor and 10% in benign tumor. The expression of PCNA correlated with prognosis and pathological differentiation. This experiment shows that EGFR, neu, PCNA and ovarian serous cancer prognosis are related, neu, PCNA and pathological differentiation have some relevance. May be to determine the pathological differentiation, clinical prognosis indicators.